Compare DNA & GBLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DNA | GBLI |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 458.6M | 444.5M |
| IPO Year | 2020 | 2010 |
| Metric | DNA | GBLI |
|---|---|---|
| Price | $6.94 | $28.52 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 3.2K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 5.13% |
| EPS Growth | ★ 46.49 | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | $170,155,000.00 | ★ $450,098,000.00 |
| Revenue This Year | N/A | $14.23 |
| Revenue Next Year | N/A | $9.68 |
| P/E Ratio | ★ N/A | $28.91 |
| Revenue Growth | N/A | ★ 2.02 |
| 52 Week Low | $5.37 | $24.28 |
| 52 Week High | $17.58 | $30.50 |
| Indicator | DNA | GBLI |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 58.27 |
| Support Level | $6.30 | $27.56 |
| Resistance Level | $7.10 | N/A |
| Average True Range (ATR) | 0.47 | 1.12 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 27.47 | 80.96 |
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
Global Indemnity Group LLC is a United States-based holding company with a diversified portfolio of property and casualty insurance-related entities. Along with its subsidiaries, the company operates in the following reportable segments: Agency and Insurance Services, Belmont Insurance Companies - Core (Belmont Core), and Belmont Insurance Companies - Non-Core (Belmont Non-Core). Maximum revenue is generated from the Belmont Core segment, which offers direct insurance and assumed reinsurance products in the E&S (Excess and Surplus) marketplace. The Agency and Insurance Services segment is focused on sourcing, underwriting, and servicing primary and assumed reinsurance business; and specialized insurance service businesses providing technology, AI-enabled marketplace, and claims services.